Patent application number | Description | Published |
20130064807 | USE OF THROMBIN MUTANTS TO INHIBIT THE ANTICOAGULATION EFFECT OF THROMBIN INHIBITORS - The present disclosure provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present disclosure include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent. In one embodiment, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered. The present disclosure further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay. | 03-14-2013 |
20130095042 | SILICA-BASED NANOPARTICLES AND METHODS OF STIMULATING BONE FORMATION AND SUPPRESSING BONE RESORPTION THROUGH MODULATION OF NF-KB - Osteoporosis, is an exceedingly common malady that leads to bone fracture and results from an imbalance in the rate of osteoblastic bone formation with respect to osteoclastic bone degradation. Nanotechnology has raised exciting possibilities for the development of novel therapeutic agents. Embodiments of the disclosure provide silica-based fluorescent nanoparticles endowed with natural bone targeting capabilities and expressing potent pro-osteoblastogenic and concomitant anti-osteoclastogenic activities in vitro and the capacity to increase bone mineral density in vivo. Embodiments of the disclosure can achieve their stimulatory effects on osteoblasts, and inhibitory effects on osteoclasts, in part by suppressing NF-KB signal transduction. Embodiments of the present disclosure provide for derivatives of silica-based nanoparticles that represent a novel class of dual anti-catabolic and pro-anabolic agents that may be applicable to the amelioration of numerous osteoporotic conditions. | 04-18-2013 |
20130122514 | METHODS FOR DETERMINATION OF PROTEIN PHOSPHATASE ACTIVITY, AND USES IN PREDICTING THERAPEUTIC OUTCOMES - One aspect of the present disclosure encompasses methods for determining a protein kinase or phosphatase activity in a biological sample, comprising: contacting in a reaction mix a first test sample and a fluorescently-labeled peptide substrate capable of being modified by a protein phosphatase or a protein kinase, contacting the reaction mix with a TiO | 05-16-2013 |
20130123618 | Imaging Agents - This invention provides amino acid derivatives useful in detecting and evaluating brain and body tumors, including (1S,2S) anti-2-[ | 05-16-2013 |
20130137760 | GAMBOGIC AMINE, A SELECTIVE TRKA AGONIST WITH NEUROPROTECTIVE ACTIVITY - Small molecule agonists, partial agonists, and antagonists for the TrkA receptor are described. The compounds are gambogic amines, where the carboxylic acid group of gambogic acid (CO | 05-30-2013 |
20130149214 | MICROVASCULAR FLUIDIC DEVICES, SYSTEMS AND METHODS RELATED THERETO - Microfluidic devices and processes are provided that relate to microvascular-sized systems configured to identify specific pathophysiological characteristics related to the interactions between, for example, blood cells and endothelial cells combined with geometric and flow constraints of microvasculature. The device may include at least one layer, the layer including a plurality of microvascularized-sized fluidic channels, the plurality of microfluidic channels being disposed in a geometric pattern. The layer may be composed of a hydrogel and/or a silicon elastomer. The channels may include subchannels of different lengths. | 06-13-2013 |
20130150332 | 9-AMINONOSCAPINE AND ITS USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS - 9-aminonoscapine, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-aminonoscapine, and methods of preparation and use thereof are disclosed. 9-aminonoscapine is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-aminonoscapine can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-aminonoscapine is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs. | 06-13-2013 |
20130164218 | HYPOXIA INDUCIBLE FACTOR-1 PATHWAY INHIBITORS AND USES ASANTICANCER AND IMAGING AGENTS - This disclosure relates to Hypoxia Inducible Factor-1 pathway inhibitors and uses as anticancer and imaging agents. In certain embodiments, the disclosure contemplates compounds and pharmaceutical compositions disclosed herein. | 06-27-2013 |
20130177222 | SYSTEMS, METHODS AND COMPUTER READABLE STORAGE MEDIA STORING INSTRUCTIONS FOR GENERATING AN IMAGE SERIES - Systems, methods, and computer-readable storage media relate to generate an image series that includes a patient image and a medical image. The patient image and the medical image may be associated based on identification information. | 07-11-2013 |
20130182929 | SYSTEMS, METHODS, AND COMPUTER READABLE STORAGE MEDIA STORING INSTRUCTIONS FOR GENERATING AN IMAGE INTEGRATING FUNCTIONAL, PHYSIOLOGICAL AND ANATOMICAL IMAGES - Systems, methods and computer-readable storage mediums relate to generating an image that includes functional, anatomical, and physiological images. The generated image may be an integrated image based on the functional image on which the anatomical and physiological images are mapped. The generated image may indicate more than one location of optimal lead placement. The generated image may be useful in pre-planning cardiac intervention procedures. | 07-18-2013 |
20130190402 | Methods Of Treating Autism With mGluR5 Antagonists - mGluR5 antagonists are used for the treatment of autism. The human treated by the methods of the invention can also have fragile X syndrome, epilepsy and anxiety. | 07-25-2013 |